<DOC>
	<DOCNO>NCT00006009</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness monoclonal antibody therapy treat patient advanced recurrent lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Advanced Recurrent Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety tolerability monoclonal antibody HuM291 patient advance recurrent CD3+ T-cell lymphoma . - Evaluate pharmacokinetics pharmacodynamics treatment regimen patient population . - Determine response patient treat regimen . OUTLINE : This dose-escalation study . Patients receive monoclonal antibody HuM291 IV 3 hour day 1-4 absence unacceptable toxicity . Patients achieve partial response , complete response recurrence , stable disease may receive therapy . Cohorts 3-6 patient receive escalate dos monoclonal antibody HuM291 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . Patients follow weekly 1 month monthly 3 month . PROJECTED ACCRUAL : A total 12-15 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm CD3+ Tcell lymphoma standard curative therapy exist Peripheral Tcell lymphoma Recurrent and/or progressive disease least 1 prior therapy Mycosis fungoides Stage IB/IIA Recurrent and/or progressive disease least 2 prior therapy Stage IIBIVB Recurrent and/or progressive disease least 1 prior therapy All Tcell lymphoma Recurrent and/or progressive disease least 1 prior therapy Evaluable disease Any nodal site mass lesion least 1.5 cm long axis physical exam CT scan Skin lesion least 1 cm long axis cutaneous lymphoma High number circulate Tcells allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : WBC least 2,000/mm^3* Absolute neutrophil count least 1,000/mm^3* Platelet count least 75,000/mm^3* NOTE : * Unless due lymphoma Hepatic : Bilirubin great 2.0 time normal* AST/ALT great 2.5 time upper limit normal* Hepatitis B C negative NOTE : * Unless due lymphoma Renal : Not specify Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : No uncontrolled illness No ongoing active infection No active malignancy except basal cell skin cancer carcinoma situ cervix HIV1 negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics Biologic therapy : At least 60 day since prior humanize chimeric antibody therapy Chemotherapy : At least 3 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy Surgery : Not specify Other : At least 30 day since prior investigational drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
</DOC>